US Stock MarketDetailed Quotes
RNAZ Transcode Therapeutics
- 0.613
- +0.014+2.35%
Close Oct 18 16:00 ET
- 0.620
- +0.007+1.13%
Post 20:01 ET
10.59MMarket Cap-248P/E (TTM)
0.641High0.605Low386.95KVolume0.630Open0.599Pre Close241.76KTurnover2.24%Turnover RatioLossP/E (Static)17.27MShares20.68852wk High7.96P/B10.58MFloat Cap0.21652wk Low--Dividend TTM17.26MShs Float5600.000Historical High--Div YieldTTM6.10%Amplitude0.216Historical Low0.624Avg Price1Lot Size
About Transcode Therapeutics Company
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Newton, MA.
Company Profile
SymbolRNAZ
Company NameTranscode Therapeutics
Listing DateJul 9, 2021
Issue Price4.00
Founded2016
CEOMr. Thomas A. Fitzgerald, M.B.A.
MarketNASDAQ
Employees10
Fiscal Year Ends12-31
Address73b Chapel Street
CityNewton
ProvinceMassachusetts
CountryUnited States of America
Zip Code02458
Phone1-857-837-3099
Company Executives
- Name
- Position
- Salary
- Thomas A. Fitzgerald, M.B.A.
- Interim President, Chief Executive Officer, Director, Vice President, Chief Financial Officer and Principal Accounting Officer
- 426.86K
- Dr. Zdravka Medarova
- Chief Scientific Officer
- --
- Dr. Philippe P. Calais, PhD
- Executive Chairman of the Board
- 112.61K
- Dr. Magda Marquet, PhD
- Independent Director
- 75.11K
- Dr. Erik Manting, PhD
- Independent Director
- 73.11K
- Dr. Anna Moore, PhD
- Scientific Advisor
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data